This edition of World TPD & Induced Proximity Summit South Korea has already taken place.
Search future editions →Events › Healthcare & MedTech
Healthcare & MedTech
The first and only industry-dedicated forum in Asia for accelerating the development of protein degraders and induced proximity-based therapeutics, featuring insights on PROTACs and novel ligases.
Attendees: R&D leaders, scientists, regulatory experts, business development, biotech, pharma, CROs, CDMOs, service providers, academia.
Exhibitor mix: Sponsors, technology partners, CROs, CDMOs, and solution providers active in TPD.
Planning for next year?
Dozens of solution providers here. You probably care about 20–30. Tell us your ICP, we'll find them.
Request intelligence →Delivery within 24 hours · $1,250
Organizer
Hanson WadePE-backed · London, United Kingdom · Founded 2008
Hanson Wade is a global conference organizer and market intelligence provider focused primarily on the life sciences and biopharma sectors.
Why people attend
To connect with global and local pharma, source PROTAC development technologies, and explore collaboration opportunities in the booming Asian TPD sector.
Exhibitor categories
Sample matches
Filtered to a Series-B SaaS ICP. Your filter will be different.
Sample Match A
example.com
"Strong ICP match: Series B, EU expansion, VP Engineering and CTO attending."
Sample Match B
example.io
"Mid-stage SaaS with active GTM motion; product-led growth signals align with ICP."
████████ ██████
████████.io
"████████████████████████████████████████."
Submit your ICP
to unlock all matches
████████ ██████
████████.io
"████████████████████████████████████████."
Submit your ICP
to unlock all matches
Speakers
25 speakers at World TPD & Induced Proximity Summit South Korea
Dr. Jaeki Min is a pharmaceutical scientist and group leader at Amgen’s Induced Proximity Platform, specializing in chemical biology and targeted protein degradation. With over 20 years of experience…
Hongbo has over 10 years of experience in drug discovery and project management at leading CROs and top biotech companies. He has successfully led the development of several small-molecule drug…
Program Manager · Global Mental Health Alliance
Dr. Kim focuses on implementing psychosocial controls in high-stress industries such as healthcare and emergency services.
Also speaking at AIHA Connect, TCEA Librarian Conference 2026
Dr. Bing Zhang obtained his Ph.D. in Biology from Durham University. He has nearly 20 years of drug discovery experiences in both research and project management. Over the course of his career…
I’m currently working on discovering de novo therapeutic targets for Huntington’s Disease (HD). HD is the third most prevalent neurodegenerative diseases, as well as the most prevalent CAG triplet…
Hwa Jin Lee is an expert in TPD field for several years, heading PLK1 degrader, an UPPThera’s current lead pipeline, to FDA IND clearance for phase 1/2a clinical trial. Also, he is in charge of…
Dr. Wooseok Han is the Chief Scientific Officer of Cyrus Therapeutics, based in Seoul, Korea. He began his industrial career in 2005 at Chiron in Emeryville, California, which was shortly thereafter…
Dr. Min Jae Lee is an internationally recognized leader in protein homeostasis research, with seminal contributions to the ubiquitin–proteasome system, autophagy…
Kanae Gamo is leading overall research as a CSO at FIMECS, Inc. She co-founded FIMECS in 2018 as a spin-out biotech from Takeda Pharmaceutical Co., Ltd. She has expertise in many techniques of…
Over 20 years of experience in the pharmaceutical industry as a medicinal chemist / chemical biologist, working for Mitsubishi Tanabe Pharma Corporation. I have led several interdisciplinary teams of…
I am a molecular and cellular biologist by training, working at the Cellular Degradation Biology Center in Seoul National University as a Research Associate Professor on the basic/
Yoshika Yamakawa is a professional at Astellas Pharma with experience spanning roles in Japan and the UK, informed by an academic background from Azabu University. Based in Canterbury, she is part of…
Founder and Chief Executive Officer of Pin Therapeutics, Korea (2017-) Founding Partner of Embedbio (The Early-Stage Investment Company Builder Specialized in Biotech and Healthcare Sectors)…
+ 9 more speakers at this event.
More Healthcare & MedTech events
Frequently asked questions